Europe News

Found 99,698 articles

• 

  Greece Goes After Novartis for Alleged Bribery and Kickbacks

  5/18/2022

  Greece’s Health Minister Thanos Plevris announced plans to sue Novartis over what he alleges are illegal practices. In addition to demanding compensation, the country is implementing a three-point plan.

• Immatics Announces First Patient Treated with ACTengine® IMA203 TCR-T in Combination with Checkpoint Inhibitor Opdivo® (nivolumab) in Patients with Advanced Solid Tumors

  5/18/2022

  The Phase 1b dose expansion cohort will evaluate safety, biological activity and initial anti-tumor activity of IMA203 TCR-T targeting PRAME in combination with nivolumab 1.

• Pre-clinical findings support the potential use of RhoVac's drug candidate, onilcamotide, across several cancers

  5/18/2022

  RhoVac AB ("RHOVAC") today, 18th May 2022, announces preclinical findings from its collaboration with St. John's Research Institute (SJRI), a unit of CBCI Society for Medical Education, in Bangalore India.

• OSE Immunotherapeutics Announces Dosing of the First Participant in a Phase 1 Study of VEL-101/FR104, a Novel Investigational Drug for Kidney Transplant Immunosuppression

  5/18/2022

  OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that the first participant has been dosed in a Phase 1 Study of VEL-101/FR104 [NCT05238493], a study sponsored and conducted by its partner in transplantation, Veloxis Pharmaceuticals, Inc., an Asahi Kasei company.

• TC BioPharm Announces Formation of Scientific Advisory Board with Renowned Cell Therapy Experts

  5/18/2022

  TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), announced today announced the formation of a scientific advisory board (SAB) to advance its gamma-delta T cell therapy, OmnImmune®, for the treatment of Acute Myeloid Leukemia (AML).

• FDA grants Orphan Drug Designation for tasquinimod in myelofibrosis

  5/18/2022

  Active Biotech AB (Nasdaq Stockholm: ACTI) today announced that the U.S. Food and Drug Administration (FDA) has granted tasquinimod Orphan Drug Designation for the treatment of myelofibrosis.

• Calliditas Therapeutics: Interim Report Q1, 2022

  5/18/2022

  During the first quarter Calliditas launched its first commercial product, TARPEYO, in the US, supported by 40 experienced specialty sales executives who were trained and in the field in late January.

• Bavarian Nordic to Manufacture First Freeze-dried Doses of Smallpox Vaccine upon Exercise of Contract Option by the U.S. Government

  5/18/2022

  Bavarian Nordic A/S announced that the U.S. Biomedical Advanced Research and Development Authority, part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, has exercised the first options under the contract to supply a freeze-dried version of JYNNEOS® smallpox vaccine, thus allowing for the first doses of this version to be manufactured and invoiced in 2023 and 2024.

• Study Results Show Long-term Efficacy of iTind Procedure

  5/18/2022

  Olympus announced the summary results of a follow-up study to measure the durability of the iTind™ procedure for treating the lower urinary tract symptoms caused by BPH.

•  Adrestia Appoints Human Genetics Leader, Professor John Perry, to Build Human Genetics Computational Platform

  5/18/2022

  Adrestia Therapeutics, a leader in synthetic rescue therapies for genetic diseases, announced the appointment of Professor John R.B. Perry as its Vice President, Human Genetics.

• Medical Microinstruments Announces Major Expansion in Pisa, Italy to Support Growth

  5/18/2022

  Medical Microinstruments SpA, a robotics company dedicated to improving clinical outcomes for patients undergoing microsurgery, announced the grand opening of its new facility in Pisa, Italy.

• XVIVO to Advance Their Digital Transformation Journey in Partnership with the World-Leading Cleveland Clinic to Increase the Number of Successful Lung Transplants

  5/18/2022

  XVIVO and the Cleveland Clinic in the US have entered a partnership in advanced analytics, XPS Live, using lung perfusion data from XVIVO's XPS machines.

• Interim report January 1 - March 31, 2022

  5/18/2022

  In the first quarter of 2022, license revenue rose 35 percent and support revenue rose 24 percent. Operating profit amounted to SEK 30 M.

• Lysogene Provides Clinical Update on AAVance Phase 2/3 Clinical Trial with Gene Therapy LYS-SAF302 for the Treatment of MPS IIIA at the 25th Annual ASGCT Meeting

  5/18/2022

  Lysogene, a phase 3 gene therapy platform company targeting central nervous system diseases, provided updated clinical data from the ongoing AAVance phase 2/3 clinical trial with the investigational gene therapy LYS-SAF302 for the treatment of MPS IIIA during the 25th Annual Meeting of the ASGCT in Washington, DC.

• Blue Light Cystoscopy continues to make news at AUA 2022

  5/18/2022

  Photocure ASA, the Bladder Cancer Company, announces the conclusion of a productive AUA 2022 Conference: the American Urological Association Annual Congress 2022, an in-person event for the first time since 2019, was held May 13-16, 2022 in New Orleans, LA, USA.

• VectorY Announces Preclinical Data on TDP-43 and Oxidized Phospholipids at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

  5/18/2022

  VectorY Therapeutics, a biotech company focusing on the development of innovative gene therapy approaches for the treatment of neurodegenerative and muscular disorders through vectorized antibodies, today announced further detail on the two presentations to be delivered at the American Society of Gene and Cell Therapy (ASGCT) Congress 2022 Annual Meeting being held May 16-19 in Washington, D.C.

• Exscientia to Report First Quarter 2022 Financial Results on May 25, 2022

  5/18/2022

  Company to host conference call and webcast on May 26, 2022 at 1:30 p.m. BST / 8:30 a.m. ET.

• NANOBIOTIX Provides First Quarter Operational and Financial Update

  5/18/2022

  NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the "Company"), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced operational progress, cash position (unaudited) for the first quarter of 2022, and extension of operating runway into Q4 2023.

• Ryvu Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

  5/18/2022

  Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, today reported financial results for the first quarter of 2022 and provided a corporate update.

• ABL AND ODIMMA THERAPEUTICS JOIN FORCES IN PERSONALIZED CANCER IMMUNOTHERAPY

  5/17/2022

  ABL Europe ( ABL ) and Odimma Therapeutics announced that they have signed a development agreement.